Article info

Original research
Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival

Authors

  1. Correspondence to Dr Jeffrey Weber; Jeffrey.Weber{at}nyulangone.org
View Full Text

Citation

Mandalá M, Larkin J, Ascierto PA, et al
Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival

Publication history

  • Accepted August 9, 2021
  • First published August 27, 2021.
Online issue publication 
October 18, 2023
  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.